Lp(a) Testing: The Heart Risk Hiding in Your Blueprint
Most heart risk factors are negotiable. You can lower your LDL with diet and medication. You can quit smoking. You can get your blood pressure under control with the right combination of lifestyle and prescriptions. But there is one risk factor that does not respond to any of that. It has been quietly built into the architecture of your cardiovascular system since before you were born, and Lp(a) testing is the only way to find out if it is there.
It is called lipoprotein(a), or Lp(a), and for decades it has been the test almost nobody ordered. That just changed.
Why Lp(a) Testing Just Became the Guideline Standard
In March 2026, the American College of Cardiology and American Heart Association, along with nine other medical societies, released a sweeping update to the guideline on managing dyslipidemia, retiring the 2018 cholesterol guideline that most of us trained on. Buried in the headlines about new LDL targets and risk calculators is a recommendation that has been a long time coming: every adult should have Lp(a) testing at least once in their lifetime.
That is a meaningful shift. The old guideline treated Lp(a) as an optional “risk enhancer” to consider in borderline cases. The new one treats it as a standard part of knowing your cardiovascular blueprint. It is something you check once and, because it is genetically locked in and stable over your lifetime, generally never need to recheck. The guideline flags anything at or above 125 nmol/L (roughly 50 mg/dL) as high, associated with about a 1.4-fold increase in lifetime risk of heart attack or stroke. Levels above 250 nmol/L roughly double that risk.¹
If you have never had this test, you are in good company. Despite a decade of guidelines nudging toward it, large health-system data show Lp(a) testing rates hovering around a fraction of a percent of adults. It is the most common heart risk factor nobody has heard of.
What Lp(a) Actually Is, in Plain English
Think of LDL cholesterol as a delivery truck dropping off cargo it should not be dropping off in your artery walls. Lp(a) is that same truck, except somebody welded a second, mismatched piece of equipment onto the back of it: a protein fragment called apolipoprotein(a), or apo(a), that is a near twin of plasminogen, the molecule your body uses to dissolve blood clots.
That structural quirk means Lp(a) does double duty as a troublemaker. It carries the same cholesterol payload as LDL into your artery walls, and because it is even more prone to oxidation, it tends to provoke more inflammation along the way.² It also acts like a decoy, competing with real plasminogen for binding sites and gumming up your body’s natural clot-clearing system, which nudges your blood toward a stickier, more clot-prone state.² In short, more plaque and a harder time cleaning it up.
Here is the part that makes it unique among lipid risk factors: Lp(a) levels are roughly 90% determined by a single gene (LPA) and are set for life by your mid-childhood. Diet, exercise, and weight loss, the levers that move LDL and triglycerides, barely touch it. That is exactly why Lp(a) testing only needs to happen once, and why it is worth knowing your number even if everything else on your lipid panel looks great.
So What Do You Actually Do About It?
This is usually where people expect a deflating answer: “there is nothing to do, so why test?” I would push back on that. Here is what an elevated Lp(a) actually changes.
It recalibrates your real risk. A “normal” LDL with a high Lp(a) is not the same low-risk picture it looks like on paper. Knowing your number can shift how aggressively we manage everything else, including LDL targets, blood pressure goals, the conversation around statins or PCSK9 inhibitors, and even decisions about imaging like a coronary calcium scan to see if elevated Lp(a) has already left fingerprints on your arteries.
It puts your family on notice. Because Lp(a) is so strongly inherited, a high result is a reason to have first-degree relatives (siblings, adult children, parents) get tested too. One test can change risk awareness for an entire family tree.
It focuses your effort on what you can control. Since Lp(a) itself will not move much, the practical strategy is to be more aggressive everywhere else: tighter LDL control, blood pressure, blood sugar, not smoking, and staying active. Some clinicians also consider PCSK9 inhibitors, which lower Lp(a) modestly (roughly 15 to 20%) as a secondary effect of their main LDL-lowering action.³
What’s coming next. A new generation of Lp(a)-specific drugs, including pelacarsen and olpasiran, are in late-stage trials and have shown they can lower Lp(a) by 80 to 95%, far more than anything available today.⁶ But these are not approved yet. The cardiovascular outcomes trials that would prove they actually prevent heart attacks are still reading out. Until then, “lower Lp(a) on paper” and “lower Lp(a) in a way proven to save lives” are two different things, and we should celebrate the first without overpromising the second.
A Test Worth a Few Minutes of Conversation
If you have never had Lp(a) testing done, this is the year the guidelines caught up to a question worth asking. It is a single blood draw, it tells you something about yourself you will likely never need to recheck, and it can meaningfully reshape how we approach everything else on your cardiovascular plan.
If you are curious where you stand, or simply have not had a real conversation about your heart health in a while, I would love to talk it through with you.
Book a free discovery call at theheartnd.com/start/
References
O’Donoghue ML, Rosenson RS, Gencer B, et al; OCEAN(a)-DOSE Trial Investigators. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. N Engl J Med. 2022;387(20):1855-1864. doi:10.1056/NEJMoa2211023. PMID: 36342163.
Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026. doi:10.1016/j.jacc.2025.11.016. PMID: 41824590.
Ugovšek S, Šebeštjen M. Lipoprotein(a), The Crossroads of Atherosclerosis, Atherothrombosis and Inflammation. Biomolecules. 2021;12(1):26. doi:10.3390/biom12010026. PMID: 35053174.
Tweneboah C, et al. Lowering of Lipoprotein(a) with Olpasiran. Cardiovasc Hematol Disord Drug Targets. 2026 Mar 23. doi:10.2174/011871529X428489260113103704. PMID: 41879443.
AIM-HIGH Investigators (Boden WE, Probstfield JL, Anderson T, et al). Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. N Engl J Med. 2011;365(24):2255-2267. doi:10.1056/NEJMoa1107579. PMID: 22085343.
HPS2-THRIVE Collaborative Group (Landray MJ, Haynes R, Hopewell JC, et al). Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. N Engl J Med. 2014;371(3):203-212. doi:10.1056/NEJMoa1300955. PMID: 25014686.
